Latest news

• Novartis sets sights on connected inhaler

  Novartis plans a 2019 launch for the new device, which will be available for its COPD portfolio of Onbrez, Breezhaler Seebri, and Ultibro Breezhaler.

• Novartis' Ultibro tops Seretide in comparative COPD trial

  of adding Seebri to LABA/inhaled corticosteroid therapy. ... To that end it signed an agreement with Pfizer last week to co-promote Ultibro and Seebri (glycopyrronium bromide) in the UK.

• Novartis' combo COPD inhaler cleared in EU

  Seebri and Onbrez, respectively.

• Boehringer’s first cancer drug leads EMA recommendations

  acting muscarinic antagonist (LAMA) present in Novartis' Seebri.

• Novartis parts with Eisai to go it alone with COPD drugs

  The companies have called time on their partnership, which covered Novartis' Onbrez, Seebri and QVA149, just over a year after it was signed. ... Novartis will now go it alone in promoting Onbrez Inhalation Capsules 150 mcg (indacaterol maleate) and